[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lite Strategy Inc (LITS)

Lite Strategy Inc (LITS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 27,237
  • Shares Outstanding, K 34,025
  • Annual Sales, $ 0 K
  • Annual Income, $ -15,950 K
  • EBIT $ -58 M
  • EBITDA $ -58 M
  • 60-Month Beta 0.21
  • Price/Sales N/A
  • Price/Cash Flow 0.12
  • Price/Book 0.47
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.60
  • Most Recent Earnings $-0.66 on 05/13/26
  • Next Earnings Date 09/25/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 843.87% (+568.30%)
  • Historical Volatility 92.27%
  • IV Percentile 99%
  • IV Rank 100.00%
  • IV High 843.87% on 06/15/26
  • IV Low 114.60% on 10/28/25
  • Expected Move (DTE 2) 0.0000 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 649
  • Volume Avg (30-Day) 73
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 14,786
  • Open Int (30-Day) 14,695
  • Expected Range 0.9200 to 0.9200

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6888 +33.57%
on 06/11/26
1.1610 -20.76%
on 05/18/26
-0.2500 (-21.37%)
since 05/15/26
3-Month
0.6888 +33.57%
on 06/11/26
1.2620 -27.10%
on 05/11/26
-0.3300 (-26.40%)
since 03/16/26
52-Week
0.6888 +33.57%
on 06/11/26
9.0000 -89.78%
on 07/18/25
-1.3100 (-58.74%)
since 06/16/25

Most Recent Stories

More News
Lite Strategy Reports Fiscal 2026 Third Quarter Results

SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (Nasdaq: LITS) (“Lite Strategy” or the “Company”), the first U.S. public company to adopt Litecoin (LTC) as its primary treasury...

LITS : 0.9200 (+14.93%)
Lite Strategy Reports Fiscal 2026 Second Quarter Results

SAN DIEGO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (Nasdaq: LITS) (“Lite Strategy” or the “Company”), the first U.S. public company to adopt Litecoin (LTC) as its primary treasury...

LITS : 0.9200 (+14.93%)
Lite Strategy Reports First Quarter Fiscal Year 2026 Results; Highlights Successful Launch of $100M Litecoin Treasury Strategy and Movement into Active Capital Market Operations

Lite Strategy, Inc. (NASDAQ:LITS) (“Lite Strategy” or “LITS”) today reported results for its first quarter ended September 30, 2025, and highlighted recent corporate

LITS : 0.9200 (+14.93%)
Lite Strategy Announces $25M Share Repurchase Program, Signaling Shift From Initial Litecoin Accumulation to Active Capital Market Operations

SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (NASDAQ: LITS) (“Lite Strategy” or “LITS”) today announced its Board of Directors has authorized a program to repurchase shares...

LITS : 0.9200 (+14.93%)
Lite Strategy Celebrates 14th Anniversary of Litecoin, Taps Institutional Signals Ahead of 2026

SAN DIEGO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (NASDAQ: LITS) (“Lite Strategy” or “LITS”), the first U.S.-listed public company to adopt Litecoin as its primary reserve asset,...

LITS : 0.9200 (+14.93%)
MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker ‘LITS’

Lite Strategy Rebrand Aligns with Company’s LTC Digital Asset Treasury Strategy Advised by GSR Ventures

MEIP : 3.07 (+10.43%)
LITS : 0.9200 (+14.93%)
Canadian Investment Regulatory Organization Trading Halt - LITS

VANCOUVER, BC , Sept. 5, 2025 /CNW/ - The following issues have been halted by CIRO:

LITS : 0.9200 (+14.93%)
LiTHOS Secures U.S. Patent, Paving the Way for Complete Lithium Refinery Operations with Broad Direct Lithium Extraction (DLE) Capabilities

/CNW/ - LiTHOS Group Ltd. ("LiTHOS" or the "Company") (CBOE CA: LITS), a company at the forefront of sustainable lithium brine extraction, is pleased to...

LITS : 0.9200 (+14.93%)
LiTHOS Provides Q3 Corporate & Operational Update

/CNW/ - LiTHOS Group Ltd. ("LiTHOS" or the "Company") (CBOE CA: LITS), a leader in sustainable lithium brine production technologies, is pleased to provide...

LITS : 0.9200 (+14.93%)
LiTHOS Announces Grant of RSUs and PSUs to Conserve Capital and Align Interests with Long-Term Growth

/CNW/ - LiTHOS Group Ltd. ("LiTHOS" or the "Company") (CBOE CA: LITS) (OTCQB: LITSF) (FSE: YU8) (WKN: A3ES4Q), today announces an important update to its...

LITSF : 0.0700 (+16.67%)
LITS : 0.9200 (+14.93%)

Business Summary

MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The Company is focused on the clinical development of its two lead isoflavone-based drug candidates, ME-143 and ME-344. MEI Pharma, Inc., formerly known as Marshall Edwards,...

See More

Key Turning Points

3rd Resistance Point 1.2165
2nd Resistance Point 1.1052
1st Resistance Point 1.0126
Last Price 0.9200
1st Support Level 0.8087
2nd Support Level 0.6974
3rd Support Level 0.6048

See More

52-Week High 9.0000
Fibonacci 61.8% 5.8251
Fibonacci 50% 4.8444
Fibonacci 38.2% 3.8637
Last Price 0.9200
52-Week Low 0.6888

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.